Targeted silencing of BAF60a in ApoE-KO mice highlights its potential as a therapeutic target in atherosclerosis, offering a novel strategy to simultaneously modulate lipid metabolism and vascular inflammation for plaque stabilization and regression. Here, SMARCD1 is linked to atherosclerosis.